<DOC>
	<DOCNO>NCT02211222</DOCNO>
	<brief_summary>This Expanded Access Program ( EAP ) consist Prerandomization Phase Randomization Phase . Only subject radioiodine-refractory DTC fulfill eligibility criterion treat . These subject treat progression disease unacceptable toxicity .</brief_summary>
	<brief_title>An Expanded Access Program With Lenvatinib Treatment Radioiodine-Refractory Differentiated Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects must histologically cytologically confirm diagnose one follow DTC subtypes : a. Papillary thyroid cancer ( PTC ) i. Follicular variant ii . Variants ( include limit : tall cell , columnar cell , cribriformmorular , solid , oxyphil , Warthin'slike , trabecular , tumor nodular fasciitislike stroma , Hurthle cell variant papillary carcinoma , poorly differentiate ) ; b.Follicular thyroid cancer ( FTC ) i. Hurthle cell ii . Clear cell iii.Insular 2 . Subjects must radioiodinerefractory resistant within 12 month radioiodine therapy one following : 1 . One lesion demonstrate iodine uptake radioiodine scan 2 . One lesion substantially increase size within 12 month radioiodine therapy , despite demonstration radioiodine activity time treatment pre posttreatment scan 3 . Cumulative activity radioiodine great 600 mCi 22 gigabecquerels ( GBq ) , last dose administer least 6 month prior study entry 3 . Subjects must receive failed treatment sorafenib RRDTC . This criterion apply outside United States sorafenib commercially available country subject resides . 4 . ECOG performance status 0 2 5 . Blood pressure ( BP ) less equal 150/90 mmHg screen without antihypertensive medication change antihypertensive medication within 1 week prior Cycle 1 Day 1 6 . Creatinine clearance great equal 30 mL/min accord Cockcroft Gault formula 7 . Adequate bone marrow function Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Hemoglobin great equal 9.0 g/dL ( corrected growth factor transfusion ) Platelet count great equal 100 x 10^9/L 8 . Adequate liver function Bilirubin le equal 1.5 x upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome Alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( less equal 5 x ULN subject liver metastasis ) . If ALP great 3 x ULN ( absence liver metastasis ) great 5 x ULN ( presence liver metastasis ) AND subject also know bone metastasis , liverspecific ALP must separate total use ass liver function instead total ALP 9 . Provide write informed consent 10 . Males females age great equal 18 year time inform consent 11 . All female must negative serum urine pregnancy test . Females childbearing potential male subject partner woman childbearing potential must use partner must use highly effective method contraception Exclusion Criteria 1 . Subjects great 1+ proteinuria urine dipstick screen test undergo 24 h urine collection quantitative assessment proteinuria . Subjects urine protein great equal 1 g/24 h ineligible . 2 . History congestive heart failure New York Heart Association ( NYHA ) Classification great II , unstable angina , myocardial infarction , serious cardiac arrhythmia , stroke within past 6 month 3 . Electrocardiogram ( ECG ) QT interval ( QTc ) interval great equal 480 msec 4 . Existing anticancer therapyrelated toxicity grade great equal 2 , except alopecia infertility 5 . History intolerance progression prior treatment lenvatinib lead discontinuation lenvatinib 6 . Any history concomitant medical condition , opinion investigator , would compromise subject 's ability safely complete protocol 7 . Females pregnant ( positive BhCG test ) breastfeed 8 . Eligible lenvatinib study open recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Thyroid Cancer</keyword>
	<keyword>Radioiodine-Refractory</keyword>
	<keyword>Differentiated</keyword>
</DOC>